@braincancerlab.bsky.social
Interdisciplinary brain cancer lab headed by @sarahannbest.bsky.social, @SaskiaFreytag.bsky.social, and @jimwhittle.bsky.social studying brain cancer at the @WEHI-research.bsky.social
.
.
Excited to see the updated results from INDIGO confirming sustained benefit of mIDH inhibition for 1st line treatment in patients with G2 gliomas. Reduced seizure frequency aligns with our findings that mIDH inhibition modulates the glioma electrical microenvironment! 👇
November 3, 2025 at 2:57 AM
Excited to see the updated results from INDIGO confirming sustained benefit of mIDH inhibition for 1st line treatment in patients with G2 gliomas. Reduced seizure frequency aligns with our findings that mIDH inhibition modulates the glioma electrical microenvironment! 👇
Reposted
A landmark research milestone, from a brilliant collaborative team, published in @natmed.nature.com
🔗 www.nature.com/articles/s41...
@sarahannbest.bsky.social @saskiafreytag.bsky.social tag.bsky.social @jimwhittle.bsky.social
🔗 www.nature.com/articles/s41...
@sarahannbest.bsky.social @saskiafreytag.bsky.social tag.bsky.social @jimwhittle.bsky.social
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial - Nature Medicine
This pilot trial showed that perioperative treatment with the isocitrate dehydrogenase (IDH) inhibitor safusidenib of patients with low-grade IDH-mutant glioma, with craniotomy and lumbar puncture bef...
www.nature.com
August 22, 2025 at 10:31 PM
A landmark research milestone, from a brilliant collaborative team, published in @natmed.nature.com
🔗 www.nature.com/articles/s41...
@sarahannbest.bsky.social @saskiafreytag.bsky.social tag.bsky.social @jimwhittle.bsky.social
🔗 www.nature.com/articles/s41...
@sarahannbest.bsky.social @saskiafreytag.bsky.social tag.bsky.social @jimwhittle.bsky.social
Reposted
So incredibly proud of my team and our collaborators.
What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors
@braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social
@wehi-research.bsky.social
www.nature.com/articles/s41...
What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors
@braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social
@wehi-research.bsky.social
www.nature.com/articles/s41...
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial - Nature Medicine
This pilot trial showed that perioperative treatment with the isocitrate dehydrogenase (IDH) inhibitor safusidenib of patients with low-grade IDH-mutant glioma, with craniotomy and lumbar puncture bef...
www.nature.com
August 22, 2025 at 10:03 PM
So incredibly proud of my team and our collaborators.
What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors
@braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social
@wehi-research.bsky.social
www.nature.com/articles/s41...
What a fantastic step forward for brain cancer clinical trials and mIDH inhibitors
@braincancerlab @jimwhittle.bsky.social @saskiafreytag.bsky.social
@wehi-research.bsky.social
www.nature.com/articles/s41...
Reposted
Researchers from WEHI, the Royal Melbourne Hospital & @petermaccc.bsky.social have achieved a brain cancer clinical trial world-first, providing hope to patients with low-grade gliomas.
🔗 www.wehi.edu.au/news/world-f...
🔗 www.wehi.edu.au/news/world-f...
August 22, 2025 at 10:31 PM
Researchers from WEHI, the Royal Melbourne Hospital & @petermaccc.bsky.social have achieved a brain cancer clinical trial world-first, providing hope to patients with low-grade gliomas.
🔗 www.wehi.edu.au/news/world-f...
🔗 www.wehi.edu.au/news/world-f...
A central question in neuro-oncology is whether therapies penetrate the tumour and exert a biological effect.
@jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research.
1/8
@jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research.
1/8
August 22, 2025 at 9:51 PM
A central question in neuro-oncology is whether therapies penetrate the tumour and exert a biological effect.
@jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research.
1/8
@jimwhittle.bsky.social and colleagues developed BrainPOP, a perioperative clinical trial platform and our lab had the pleasure of leading the translational research.
1/8